ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1043

Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study

Mehmet Hocaoglu1, Mark Davis2, Maria Valenzuela-Almada3, Jesse Dabit2, Shirley-Ann Osei-Onomah2, Sebastian Vallejo-Ramos2, Tina Gunderson2, Kurt Greenlund4, Kamil Barbour4, Cynthia Crowson5 and Ali Duarte-Garcia2, 1University of Maryland Medical Center, Midtown Campus, Baltimore, MD, 2Mayo Clinic, Rochester, MN, 3Division of Rheumatology, Mayo Clinic, Rochester, MN, 4Centers for Disease Control, Atlanta, GA, 5Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: Cutaneous

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in CLE patients is scarce and the extent of multimorbidity is uncertain. In this population-based study, we aimed to characterize the prevalence of multimorbidity in CLE patients.

Methods: Prevalent CLE cases from a well-defined 27-county region in the United States were included in our study. Cases with concomitant systemic lupus erythematosus (SLE) meeting ACR/EULAR 2019 criteria were excluded. Subjects identified as CLE were age-, sex-, race-, and county-matched to non-CLE subjects from the same population. A five-year lookback period was used for diagnostic codes to determine the presence of comorbidities. Two or more codes ≥30 days apart were used to define a comorbidity. A previously published list of 44 comorbidities was considered (England et al. ARD 2020). CLE and SLE codes were excluded from the analysis. Two or more comorbidities were defined as multimorbidity, 5 or more as substantial multimorbidity. Logistic regression models adjusted for age and sex were used.

Results: 303 CLE patients were matched to 303 non-CLE controls from the same population. The mean age was 59.4 (SD 15.7) years. 72.9% were female. 90.8% were White. CLE patients had 4.7 comorbidities on average compared to 4.0 of non-CLE subjects. Multimorbidity was present in 79.5% CLE vs. 65.7% non-CLE (OR:2.27; 95CI:1.53-3.38) and substantial multimorbidity was present in 43.9% CLE patients vs. 34.3% non-CLE subjects (OR:1.65; 95CI:1.14-2.38). Fibromyalgia, liver disease, chronic obstructive pulmonary disease (COPD), hypertension, anemia, and hypothyroidism were significantly more common in CLE patients compared to controls (Table).

Conclusion: In this population-based study, CLE patients were 2 times more likely to have multimorbidity compared to the general population. It is unclear if the driver of multimorbidity in CLE is the disease itself, treatments, or a combination thereof.


Disclosures: M. Hocaoglu, None; M. Davis, None; M. Valenzuela-Almada, None; J. Dabit, None; S. Osei-Onomah, None; S. Vallejo-Ramos, None; T. Gunderson, None; K. Greenlund, None; K. Barbour, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Hocaoglu M, Davis M, Valenzuela-Almada M, Dabit J, Osei-Onomah S, Vallejo-Ramos S, Gunderson T, Greenlund K, Barbour K, Crowson C, Duarte-Garcia A. Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-multimorbidity-in-cutaneous-lupus-erythematosus-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-multimorbidity-in-cutaneous-lupus-erythematosus-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology